Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD, a direct-to-patient telehealth company, will report its Q2 financial results on August 11, 2022, after market close. A conference call for investors is scheduled for the same day at 4:30 PM ET to discuss the results and provide updates. LifeMD operates in all 50 states and offers virtual healthcare services, including primary care and specialized treatments, leveraging its technology and nationwide pharmacy network.
LifeMD has announced a major expansion of its Virtual Primary Care platform, now addressing over 200 common medical conditions, including COVID. The company's CEO, Justin Schreiber, highlights the potential for growth and the impact on American healthcare. The platform enables patients to access treatments and prescription medications affordably, showcasing a shift from product-oriented telehealth to full-spectrum care. LifeMD aims to enhance healthcare accessibility through its proprietary technology and nationwide pharmacy network.
LifeMD, a direct-to-patient telehealth company, has declared a cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP). This dividend is set for payment on July 15, 2022, to the shareholders who are on record by the close of business on July 5, 2022.
LifeMD aims to enhance healthcare access through a portfolio of services including virtual primary care, diagnostics, and specialized treatments.
LifeMD, Inc. (NASDAQ: LFMD) reported a 60% increase in first quarter 2022 revenue, reaching $29.0 million, driven by a 70% surge in telehealth services. Adjusted EPS improved by 14% sequentially to $(0.25). The company maintains its goal of achieving Adjusted EBITDA profitability by Q4 2022, with a cash balance of $25.1 million and no debt. Significant acquisitions were completed, and operational efficiencies were noted, despite advertising market challenges. The Q1 results illustrate LifeMD's strategic growth plans and operational scaling.
LifeMD, Inc. (NASDAQ: LFMD) announced that it will release its financial results for Q1 2022 on May 13, 2022, before market open. The company will host a conference call at 8:00 AM ET the same day to discuss these results and provide a corporate update. LifeMD is a telehealth company offering virtual primary care and specialized treatments across all 50 states, leveraging technology and a nationwide pharmacy network to enhance healthcare accessibility.
LifeMD, a prominent telehealth company, will participate in two key conferences: the H.C. Wainwright Conference from May 23–26, 2022, featuring on-demand presentations and one-on-one meetings, and the B. Riley Securities 22nd Annual Institutional Investor Conference on May 26, 2022, at 11:50 AM ET. Investors can register for these events through provided links. LifeMD continues to enhance access to affordable healthcare via its virtual services across the U.S., catering to various health needs.
LifeMD, Inc. (NASDAQ: LFMD), a prominent telehealth provider, announced its participation in the 21st Annual Needham Virtual Healthcare Conference scheduled for April 11-14, 2022. The company will present on April 13 at 3:00 PM ET and will offer one-on-one meetings for investors. LifeMD provides a wide range of telehealth services across all 50 states, focusing on primary care, diagnostics, and specialized treatments. The company's goal is to enhance access to affordable healthcare through its technology platform and mail-order pharmacy network.
LifeMD, Inc. (NASDAQ: LFMD/LFMDP) has declared a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock. This dividend will be payable on April 15, 2022, to shareholders on record as of April 5, 2022. The company leverages its telehealth platform to enhance healthcare access and affordability across the United States, catering to various health conditions. LifeMD remains committed to expanding its services and outreach within the telehealth sector.
On March 23, 2022, LifeMD, Inc. (NASDAQ: LFMD) launched NavaMD™, a clinically studied OTC skincare line designed for women, incorporating over 35 patents and proprietary enzyme technology, Aquabeautine XL®. This innovative product line includes a cleanser, serum, moisturizer, and eye cream, all dermatologist-tested and suitable for various skin types. LifeMD aims to enhance telehealth offerings while ensuring personalized skincare solutions. The company's strategy continues to focus on expanding proprietary products in dermatology, leveraging its telehealth platform and expert medical team.
LifeMD, Inc. (NASDAQ: LFMD) announced its participation in the KeyBanc Virtual Healthcare Conference on March 22-23, 2022. CFO Marc Benathen will present on March 22 at 3:45 PM EST. LifeMD is a telehealth company operating across 50 states, focusing on virtual primary care, diagnostics, and specialized treatments.
This participation highlights their commitment to enhancing healthcare access through innovative technology and a nationwide mail-order pharmacy network. For registration inquiries, please contact KeyBanc's sales representatives.